In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Thomas Lund*, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Nordic Myeloma Study Group

*Corresponding author for this work
Original languageEnglish
Article number65
JournalBlood Cancer Journal
Volume14
Issue number1
ISSN2044-5385
DOIs
Publication statusPublished - 15 Apr 2024

Cite this